Clinical Trial Update: Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital [Phase 4]

View source ↗

Summary

Phase 4 study evaluating the efficacy and safety of Pegnano Plus Barivir (Ribavirin) in treatment-naïve patients with Chronic Hepatitis C has completed at KienG…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegnano Plus Barivir (Ribavirin)

Snippet

Sponsor: Nanogen Pharmaceutical Biotechnology Joint Stock Company | Conditions: Chronic Hepatitis C | Phase 4 | Status: COMPLETED | Results posted: 2025-06-29